All In MedTech

FDA Clearance Tracker · P010019

FOCUS NIGHT AND DAY (LOTRAFILCON A) SOFT CONTACT LENSES

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Oct 11, 2001 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Oct 11, 2001

Approved

Time to decision

204 days

Received Mar 21, 2001. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P010019
Device name
FOCUS NIGHT AND DAY (LOTRAFILCON A) SOFT CONTACT LENSES
Applicant location
Fort Worth, TX
Received
Mar 21, 2001
Decided
Oct 11, 2001
Decision
Approved
Supplements
83 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 886.5925
Specialty
Ophthalmology

Every decision under product code LPM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE FOCUS NIGHT AND DAY (LOTRAFILCON A) SOFT CONTACT LENSES FOR EXTENDED WEAR. THE DEVICE WILL BE MARKETED WITH THE FOLLOWING TRADE NAMES AND INDICATIONS: FOCUS NIGHT AND DAY (LOTRAFILCON A) SOFT CONTACT LENSES ARE INDICATED FOR THE OPTICAL CORRECTION OF REFRACTIVE AMETROPIA (MYOPIA AND HYPEROPIA) IN PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES AND WITH UP TO APPROXIMATELY 1.50 DIOPTERS OF ASTIGMATISM. FOCUS NIGHT AND DAY TORIC (LOTRAFILCON A) SOFT CONTACT LENSES ARE INDICATED FOR THE OPTICAL CORRECTION OF REFRACTIVE AMETROPIA (MYOPIA AND HYPEROPIA IN PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES WITH 6.00 DIOPTERS (D) OR LESS OF ASTIGMATISM. FOCUS NIGHT AND DAY PROGRESSIVES (LOTRAFILCON A) SOFT CONTACT LENSES ARE INDICATED FOR THE OPTICAL CORRECTION OF REFRACTIVE AMETROPIA (MYOPIA AND HYPEROPIA) AND/OR PRESBYOPIA IN PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES WHO MAY REQUIRE A READING ADDITION OF +3.00 DIOPTERS (D) OR LESS AND WHO MAY HAVE UP TO APPROXIMATELY 1.50 DIOPTERS OF ASTIGMATISM. THE LENSES MAY BE PRESCRIBED FOR EXTENDED WEAR FOR UP TO 30 NIGHTS OF CONTINUOUS WEAR, WITH REMOVAL FOR DISPOSAL, OR CLEANING AND DISINFECTION PRIOR TO REINSERTION, AS RECOMMENDED BY THE EYE CARE PROFESSIONAL.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LPM. The earliest in FDA's data is N16895, decided Mar 18, 1971.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Alcon Laboratories, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.